biontech se

With COVID cases on the rise in China, the government has approved Livzon Pharmaceutical's COVID-19 vaccine as a booster, in hopes of having as many people boosted as possible.

Pfizer Inc and BioNTech's COVID vaccine was approved for use in children under 5 years old in June, and new studies have shown the vaccine to be 73.2% effective within that age group.

Pfizer Inc and BioNTech announced on Monday that they are looking for the U.S. to approve their retooled COVID booster, which targets the omicron variant.

CureVac is suing Pfizer's German partner BioNTech for alleged patent infringement related to the development of their mRNA vaccines against COVID-19.

The U.S. Food and Drug Administration (FDA) amended the emergency use authorization for Pfizer-BioNTech COVID-19 vaccine. The agency is allowing the use of a single booster dose in kids ages 5 to 11.

Two doses of the Pfizer Inc. and BioNTech SE COVID-19 vaccine was protective against severe disease in children aged 5 to 11 during the recent omicron variant surge, but quickly lost most of its ability to prevent infection in the age group, according to a study by New York State researchers.

Pfizer and BioNTech said Tuesday that the companies had asked the Food and Drug Administration (FDA) to authorize their COVID-19 vaccine for emergency use in children younger than 5 years old.

COVID-19 vaccine-makers Pfizer and BioNTech announced Tuesday that the companies would test an omicron-specific vaccine candidate in healthy adults ages 18 to 55.

Pfizer Inc. expects the latest results from a clinical trial for kids under the age of 5 of the COVID-19 vaccine it developed with Germany's BioNTech SE by April, a top company scientist said on Wednesday.

Pfizer CEO Albert Bourla said Wednesday that the company's COVID-19 booster shot would be enough to "maintain protection" against the omicron variant.